p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations Elisa SensiMariella TancrediMaria A. Caligo OriginalPaper Pages: 1 - 9
E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide Sehwan HanKyeongmee ParkHong-Yong Kim OriginalPaper Pages: 11 - 16
Familial Breast Cancer: Scope for More Susceptibility Genes? Kari HemminkiCharlotta Granström OriginalPaper Pages: 17 - 22
Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™) Ilka B. FuchsSolveig LandtGerhard Schaller OriginalPaper Pages: 23 - 28
Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread Bernd GerberEva SeitzKlaus Friese OriginalPaper Pages: 29 - 37
Predictive Factors for the Status of Non-sentinel Nodes in Breast Cancer Patients with Tumor Positive Sentinel Nodes Vincent van ItersonMarjut LeideniusKarl von Smitten OriginalPaper Pages: 39 - 45
Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer N. BossardF. DescotesJ. Estève OriginalPaper Pages: 47 - 59
Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer Anne-Renee HartmanAmy GrekowiczFrank E. Stockdale OriginalPaper Pages: 61 - 69